MAPK8 and cancer: Given that the activation of JNK signalling has a tumour suppressor role65–67 in many contexts (but a tumour promotor role in others contexts66–69), the apparently enhanced survival of patients with tumours that have JNK pathway gene mutations suggests that, whenever these mutations have any impact on cancers at all, they may most commonly promote anti-tumour activity.